[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"invasive-candidiasis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:invasive-candidiasis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100497900","comparison-of-uncomplicated-candidemia-therapy-duration-in-children-100497900",false,"NCT05763251","Comparison of Uncomplicated Candidemia Therapy Duration in Children","Short Course Versus Standard Course Antifungal Therapy for Uncomplicated Candidemia in Children and Adolescents: A Multi-Center Randomized Controlled Trial","COUNT","Inclusion Criteria:\n\n1. Age \\> 120 days at the time of the first negative blood culture at any participating site;\n2. Candidemia with at least one positive blood culture for any Candida spp;\n3. Receiving\u002Freceived an echinocandin (caspofungin, micafungin, anidulafungin, or rezafungin) as primary antifungal therapy for candidemia for at least 2 days from day of first negative culture with continuation of uninterrupted systemic antifungal therapy at the time of enrollment);\n4. Sustained clearance of Candida spp. defined as negative blood culture(s) obtained after onset of candidemia and before day of randomization;\n5. Partial or complete clinical response, as defined by published guidelines (Table 5), on or before day of randomization;\n6. Between the onset of qualifying candidemia and randomization, no suspicion of disseminated candidiasis by patient's clinical team or, if deemed clinically necessary, documented negative radiological imaging such as an abdominal ultrasound or abdominal CT scan.\n\nExclusion Criteria:\n\n1. Already receiving antifungal therapy for a previously diagnosed systemic invasive fungal disease;\n2. Neutropenic (absolute neutrophil count \\\u003C 500 cells\u002Fµl) at the time of enrollment or anticipated to be neutropenic in the week following randomization;\n3. Have an underlying condition that requires them to be on antifungal prophylaxis when not receiving directed therapy for an invasive fungal disease;\n4. Previous enrollment in this trial;\n5. Females of childbearing age with a current pregnancy diagnosis or without a negative pregnancy test for their current admission;\n6. A documented DNR order;\n7. Have an implantable cardiac device (e.g., ventricular assist device, pacemaker)","ALL","120 Days",{"count":20,"type":21},420,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to compare antifungal therapy duration in pediatric uncomplicated candidemia. The specific aims are:\n\n* Compare the desirability of outcome ranking in children with uncomplicated candidemia randomized to 7 additional days of antifungal therapy (standard-course) versus no additional antifungal therapy (short-course) after already receiving 7 days of echinocandin therapy.\n* Compare the 14-day desirability of outcome measure for subjects with a negative and those with a positive T2Candida® biomarker at day 7 of therapy within randomized groups.\n\nParticipants meeting eligibility criteria will be approached and consented between day 5 and 7 of primary systemic antifungal therapy. On day 7 of primary systemic antifungal therapy, inclusion and exclusion criteria will again be reviewed for consented patients and those still eligible will be randomized 1:1 to the two study arms. Researchers will compare no additional antifungal therapy (short-course) versus 7 additional days of systemic antifungal therapy (standard-course) in pediatric patients with uncomplicated candidemia who have already received 7 days of primary systemic antifungal therapy to see if shorter durations are as effective as longer durations in treating uncomplicated candidemia.",[27],"Invasive Candidiasis","RECRUITING","2026-04-15",{"date":31,"type":32},"2026-04-17","ACTUAL",{"date":34,"type":32},"2023-09-08",{"date":36,"type":21},"2032-06-30",{"name":38,"class":39},"Arkansas Children's Hospital Research Institute","OTHER",22,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":17,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":53,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":5},"100551135","invasive-candidiasis-in-critical-care-100551135","NCT06456151","Invasive Candidiasis in Critical Care","Inclusion Criteria:\n\n* critically ill patients\n* new onset sepsis\n* rise in body temperature \\>38°C according to The Third Consensus Definitions for Sepsis and Septic Shock\n* colonization with Candida spp. from more than 1 non-sterile site\n* body temperature \\>38 °C despite 5 days of broad-spectrum antibiotic therapy with the presence of at least 1 of the following risk factors: abdominal surgery, secondary peritonitis, pancreatitis, central venous catheter (CVC) insertion, total parenteral nutrition (CPV), dialysis, steroid therapy, immunosuppressive therapy, or liver transplantation\n* microbiological test results will be reviewed and categorized based on whether Candida sp. is isolated from at least 2 non-sterile sites (±3 days) and whether there is an alternative microbiological diagnosis.\n\nExclusion Criteria:\n\n* not signing the informed consent with participation in the study\n* administration of antifungal therapy prior to collection of the biological material required for the study","12 Months",{"count":49,"type":21},100,"OBSERVATIONAL","The combination of acute phase marker monitoring and the \"T2Candida\" assay (name of the test) will represent an acceleration of the identification of the causative agent of mycotic infection, a significant improvement in the specificity and positive predictive value of this strategy in the diagnosis of invasive candidiasis and candidemia in ICU patients, thereby improving the clinical condition of patients and reducing the cost of specific antifungal therapy.",[27],[54,55,56],"invasive candidiasis","biomarkers","candida sepsis","2025-06-02",{"date":59,"type":32},"2025-06-05",{"date":61,"type":32},"2024-04-11",{"date":63,"type":21},"2027-12",{"name":65,"class":39},"University Hospital Ostrava"]